Pharmacokinetic evaluation and antitumor potency of liposomal nanoparticle encapsulated cisplatin targeted to CD24‑positive cells in ovarian cancer

K Ashihara(Osaka Medical and Pharmaceutical University), Masahide Ohmichi(Osaka University of Pharmaceutical Sciences), Tomohito Tanaka, Satoshi Tunetoh(Osaka Medical and Pharmaceutical University), Masami Hayashi(Yamagata University), Yoshito Terai(Osaka Medical and Pharmaceutical University), Satoe Fujiwara(Osaka University of Pharmaceutical Sciences), Hiroshi Sasaki(Jikei University School of Medicine), Kazuya Maeda(Kumamoto University), Yoshimichi Tanaka(Osaka Medical and Pharmaceutical University)
Oncology Letters
January 9, 2020
10.3892/ol.2020.11279
Cited by 11

Related Papers

Estrogen Induces the Akt-dependent Activation of Endothelial Nitric-oxide Synthase in Vascular Endothelial Cells
|Journal of Biological Chemistry|2001|387
Inhibition of BAD phosphorylation either at serine 112 via extracellular signal-regulated protein kinase cascade or at serine 136 via Akt cascade sensitizes human ovarian cancer cells to cisplatin.
|PubMed|2000|249
Inhibition of NFκB Increases the Efficacy of Cisplatin in in Vitro and in Vivo Ovarian Cancer Models
|Journal of Biological Chemistry|2004|212
Estrogen Suppresses Transcription of Lipoprotein Lipase Gene
|Journal of Biological Chemistry|2000|209
Inhibition of Extracellular Signal-regulated Protein Kinase or c-Jun N-terminal Protein Kinase Cascade, Differentially Activated by Cisplatin, Sensitizes Human Ovarian Cancer Cell Line
|Journal of Biological Chemistry|1999|174